Classification of recombinant factor VIII products and implications for clinical practice: A systematic literature review

Documenti analoghi

• Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis
  di: Daniel Kraemmer, et al.
  Pubblicazione: (2025)
• Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review
  di: Paul Saultier, et al.
  Pubblicazione: (2024)
• The haemophilia joint health score for the assessment of joint health in patients with haemophilia
  di: Cihan Ay, et al.
  Pubblicazione: (2024)
• Efficacy and Safety of rVIII‐SingleChain in Surgical Prophylaxis
  di: Faraizah Abdul Karim, et al.
  Pubblicazione: (2025)
• Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
  di: Christian Pfrepper, et al.
  Pubblicazione: (2024)